Lynne Garrity-Ryan

1.4k citations

25 papers · 1.1k indexed · h-index 15

Co-authors: Amy Manley Evan Tzanis Joanne N. Engel Barbara I. Kazmierczak Judith N. Steenbergen Stephen Villano Sébastien Tanaka Anita Das
Topics: Antibiotic Resistance in Bacteria (11 papers)Antimicrobial Resistance in Staphylococcus (10 papers)Antibiotics Pharmacokinetics and Efficacy (8 papers)
Cited by: Molecular Medicine Applied Microbiology and Biotechnology Endocrinology
Journals: New England Journal of Medicine Journal of Clinical Investigation Journal of Medicinal Chemistry
Partner nations: United States Romania United Kingdom

In The Last Decade

Lynne Garrity-Ryan

24 papers receiving 1.1k citations

Peers

Countries citing papers authored by Lynne Garrity-Ryan

Since Specialization

Citations

This map shows the geographic impact of Lynne Garrity-Ryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynne Garrity-Ryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynne Garrity-Ryan more than expected).

Fields of papers citing papers by Lynne Garrity-Ryan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynne Garrity-Ryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynne Garrity-Ryan. The network helps show where Lynne Garrity-Ryan may publish in the future.

Co-authorship network of co-authors of Lynne Garrity-Ryan

This figure shows the co-authorship network connecting the top 25 collaborators of Lynne Garrity-Ryan. A scholar is included among the top collaborators of Lynne Garrity-Ryan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynne Garrity-Ryan. Lynne Garrity-Ryan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia 2021 ·International Journal of Infectious Diseases ·Antoni Torres,Lynne Garrity-Ryan,(unknown),Judith N. Steenbergen,Paul B. Eckburg,Anita Das,(unknown),Amy Manley,Evan Tzanis,Paul C. McGovern	11
2	Sub-growth-inhibitory concentrations of omadacycline inhibit Staphylococcus aureus haemolytic activity in vitro 2021 ·JAC-Antimicrobial Resistance ·(unknown),Sébastien Tanaka,(unknown),Lynne Garrity-Ryan	1
3	Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment 2020 ·International Journal of Antimicrobial Agents ·Oliver A. Cornely,Thomas M. File,Lynne Garrity-Ryan,Surya Chitra,Robert Noble,Paul C. McGovern	6
4	1202. Subinhibitory Concentrations of Omadacycline Inhibit Staphylococcus aureus Hemolytic Activity in Vitro 2020 ·Open Forum Infectious Diseases ·(unknown),Sébastien Tanaka,(unknown),Lynne Garrity-Ryan	1
5	Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial 2019 ·The Lancet Infectious Diseases ·William O’Riordan,(unknown),(unknown),(unknown),Lynne Garrity-Ryan,Anita Das,Paul B. Eckburg,Amy Manley,Judith N. Steenbergen,Evan Tzanis,Paul C. McGovern,Evan Loh	73
6	Omadacycline for Community-Acquired Bacterial Pneumonia 2019 ·New England Journal of Medicine ·(unknown),Monica Popescu,(unknown),Ismail Mitha,William Nseir,Andrzej Madej,(unknown),Anita Das,Lynne Garrity-Ryan,Judith N. Steenbergen,Amy Manley,Paul B. Eckburg,Evan Tzanis,Paul C. McGovern,Evan Loh	171
7	Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study 2019 ·Antimicrobial Agents and Chemotherapy ·J. Scott Overcash,(unknown),Lynne Garrity-Ryan,Judith N. Steenbergen,Stephen A. Bai,Surya Chitra,Amy Manley,Evan Tzanis	29
8	110. Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies 2019 ·Open Forum Infectious Diseases ·George Sakoulas,Paul B. Eckburg,Amy Manley,Evan Tzanis,Lynne Garrity-Ryan,Anita Das,(unknown),(unknown),Paul C. McGovern	1
9	700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies 2019 ·Open Forum Infectious Diseases ·Manjunath P. Pai,Mark H. Wilcox,(unknown),Surya Chitra,Lynne Garrity-Ryan,Paul C. McGovern	1
10	Cardiac Safety of Omadacycline in the IV/oral Phase 3 Acute Bacterial Skin and Skin Structure Infection (ABSSSI) and in the IV/oral Phase 3 Community-acquired Bacterial Pneumonia (CABP) Studies 2017 ·Open Forum Infectious Diseases ·Börje Darpö,Evan Tzanis,Lynne Garrity-Ryan,Amy Manley,Paul C. McGovern,Evan Loh	4
11	A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study) 2017 ·Open Forum Infectious Diseases ·(unknown),Monica Popescu,(unknown),Ismail Mitha,(unknown),Andrzej Madej,(unknown),Anita Das,Lynne Garrity-Ryan,Judith N. Steenbergen,Amy Manley,Paul B. Eckburg,Stephen Villano,Evan Tzanis,Paul C. McGovern,Evan Loh	11
12	Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function 2017 ·Antimicrobial Agents and Chemotherapy ·Jolene Kay Berg,Evan Tzanis,Lynne Garrity-Ryan,Stephen A. Bai,Surya Chitra,Amy Manley,Stephen Villano	38
13	Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens 2017 ·Antimicrobial Agents and Chemotherapy ·(unknown),Evan Tzanis,Lynne Garrity-Ryan,Stephen A. Bai,Surya Chitra,Amy Manley,Stephen Villano	32
14	Small Molecule Inhibitors of LcrF, a Yersinia pseudotuberculosis Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model 2010 ·Infection and Immunity ·Lynne Garrity-Ryan,(unknown),Joan-Miquel Balada-Llasat,Victoria J. Bartlett,Atul Kumar Verma,Michael L. Fisher,Cynthia Castillo,Warangkhana Songsungthong,Sébastien Tanaka,Stuart B. Levy,Joan Mecsas,Michael N. Alekshun	62
15	N-Hydroxybenzimidazole inhibitors of ExsA MAR transcription factor in Pseudomonas aeruginosa: In vitro anti-virulence activity and metabolic stability 2010 ·Bioorganic & Medicinal Chemistry Letters ·Mark C. Grier,Lynne Garrity-Ryan,Victoria J. Bartlett,(unknown),Peter Donovan,(unknown),Michael N. Alekshun,Sébastien Tanaka,Michael P. Draper,Stuart B. Levy,(unknown)	33
16	The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T–mediated virulence 2007 ·Journal of Clinical Investigation ·Priya Balachandran,Leonard L. Dragone,Lynne Garrity-Ryan,(unknown),Arthur Weiss,Joanne N. Engel	35
17	MarA, SoxS and Rob function as virulence factors in an Escherichia coli murine model of ascending pyelonephritis 2006 ·Microbiology ·Paul Casaz,Lynne Garrity-Ryan,David McKenney,(unknown),Stuart B. Levy,Sébastien Tanaka,Michael N. Alekshun	30
18	The ADP Ribosyltransferase Domain of Pseudomonas aeruginosa ExoT Contributes to Its Biological Activities 2003 ·Infection and Immunity ·Lynne Garrity-Ryan,Sasha H. Shafikhani,Priya Balachandran,(unknown),Javin P. Oza,(unknown),Jennifer L. Sargent,Xiaofeng Fang,Stuart J. Cordwell,Michael A. Matthay,Joanne N. Engel	65
19	Pseudomonas aeruginosa ExoT inhibits in vitro lung epithelial wound repair 2001 ·Cellular Microbiology ·Thomas Geiser,Barbara I. Kazmierczak,Lynne Garrity-Ryan,Michael A. Matthay,Joanne N. Engel	53
20	The Arginine Finger Domain of ExoT Contributes to Actin Cytoskeleton Disruption and Inhibition of Internalization ofPseudomonas aeruginosaby Epithelial Cells and Macrophages 2000 ·Infection and Immunity ·Lynne Garrity-Ryan,Barbara I. Kazmierczak,Robert Kowal,James C. Comolli,Alan R. Hauser,Joanne N. Engel	156

About Lynne Garrity-Ryan

Lynne Garrity-Ryan is a scholar working on Applied Microbiology and Biotechnology, Molecular Medicine and Endocrinology, having authored 25 papers that have together received 1.1k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (11 papers), Antimicrobial Resistance in Staphylococcus (10 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). The work is most often cited by research in Molecular Medicine (473 citations), Applied Microbiology and Biotechnology (153 citations) and Endocrinology (206 citations). Lynne Garrity-Ryan has collaborated with scholars based in United States, Romania and United Kingdom. Frequent co-authors include Amy Manley, Evan Tzanis, Joanne N. Engel, Barbara I. Kazmierczak, Judith N. Steenbergen, Stephen Villano, Sébastien Tanaka, Anita Das, Paul B. Eckburg and Surya Chitra. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact